Nasdaq grants RenovoRx (RNXT) new deadline to fix $1 bid price

(Moderate)

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

RenovoRx, Inc. reported that Nasdaq has granted it a second 180-day period, until December 28, 2026, to regain compliance with the exchange’s $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

To regain compliance during this second period, the company’s common stock must close at or above $1.00 per share for at least 10 consecutive business days, after which Nasdaq would issue written confirmation. If RenovoRx does not meet this standard by the new deadline, Nasdaq will notify the company that its common stock will be delisted, though RenovoRx would then have the opportunity to appeal the determination to a Nasdaq Hearings Panel.

Positive

None.

Negative

Ongoing Nasdaq bid-price deficiency and delisting risk: RenovoRx has not regained compliance with Nasdaq’s $1.00 minimum bid price and faces potential delisting if it cannot meet the requirement by December 28, 2026.

Insights

RenovoRx gains more time but still faces Nasdaq delisting risk.

RenovoRx remains out of compliance with Nasdaq’s $1.00 minimum bid price, but has secured a second 180-day window to fix the issue. This keeps the stock on the Nasdaq Capital Market for now, avoiding immediate removal.

The company must achieve a closing bid of at least $1.00 for 10 consecutive business days before December 28, 2026. Failure to do so would trigger a delisting notice, although RenovoRx could then request a hearing before a Nasdaq Hearings Panel, which introduces additional procedural steps and uncertainty.

Investors may focus on whether the share price meets the minimum bid price requirement during the second compliance period. Subsequent company disclosures may clarify any actions taken to support continued Nasdaq listing ahead of the December 28, 2026 deadline.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice or transferred its listing to a different exchange.

Key Figures

Initial compliance deadline: June 30, 2026 Second compliance deadline: December 28, 2026 Minimum bid price: $1.00 per share +3 more

6 metrics

Initial compliance deadline June 30, 2026 End of first 180-day Nasdaq minimum bid price compliance period

Second compliance deadline December 28, 2026 End of second 180-day Nasdaq minimum bid price compliance period

Minimum bid price $1.00 per share Required closing bid price for continued Nasdaq Capital Market listing

Compliance trading period 10 business days Required consecutive days with $1.00+ closing bid price

Second compliance period length 180 calendar days Additional time granted by Nasdaq on July 1, 2026

Deficiency notice date December 31, 2025 Date Nasdaq notified RenovoRx of minimum bid price failure

Key Terms

Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5810(c)(3)(A), Emerging growth company, +1 more

5 terms

Minimum Bid Price Requirement financial

"its common stock had failed to comply with the $1.00 minimum bid price required for continued listing"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Nasdaq Listing Rule 5550(a)(2) regulatory

"the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)"

Nasdaq Listing Rule 5810(c)(3)(A) regulatory

"Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was initially provided 180 calendar days"

Emerging growth company regulatory

"Emerging growth company Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Hearings Panel regulatory

"At that time, the Company may appeal Nasdaq’s determination to a Hearings Panel."

A hearings panel is a small group of officials or experts who hold formal sessions to review evidence, question parties, and make decisions about regulatory compliance, discipline, or approvals. Think of it like a review board or courtroom for business and market issues: its findings can lead to fines, changes in a company’s permissions, or even delisting. Investors pay attention because the panel’s rulings can directly affect a company’s operations, reputation and share price.

FAQ

What did RenovoRx (RNXT) announce about its Nasdaq listing status?

RenovoRx announced that Nasdaq granted it a second 180-day compliance period ending December 28, 2026. The company is still below the $1.00 minimum bid price required to remain listed on the Nasdaq Capital Market.

What is the minimum bid price requirement affecting RenovoRx (RNXT)?

Nasdaq requires RenovoRx’s common stock to maintain a closing bid price of at least $1.00 per share. The stock must trade at or above this level for a minimum of 10 consecutive business days to regain continued listing compliance.

How long is RenovoRx’s new Nasdaq compliance period and when does it end?

RenovoRx received an additional 180-calendar-day compliance period from Nasdaq. This second compliance period expires on December 28, 2026, giving the company more time to restore its share price to Nasdaq’s $1.00 minimum bid threshold.

What happens if RenovoRx (RNXT) cannot meet Nasdaq’s bid price rule by December 28, 2026?

If RenovoRx cannot demonstrate compliance with the $1.00 minimum bid price by December 28, 2026, Nasdaq will issue written notification that its common stock will be delisted from the Nasdaq Capital Market, subject to the company’s right to appeal.

Can RenovoRx appeal a potential Nasdaq delisting decision?

Yes. If Nasdaq notifies RenovoRx that its common stock will be delisted after failing the bid price requirement, the company may appeal the determination to a Nasdaq Hearings Panel, which can review and potentially modify the delisting decision.

Why did RenovoRx previously receive a Nasdaq deficiency notice?

RenovoRx received a Nasdaq deficiency notice on December 31, 2025, because its common stock failed to meet the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/02/2026 - 08:30 AM Accepted by SEC EDGAR 07/02/2026 - 08:30 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 1, 2026

RENOVORX, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40738

27-1448452

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2570 W El Camino Real, Suite 640

Mountain View, CA

94040

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 284-4433

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		RNXT		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported, on December 31, 2025, RenovoRx, Inc., a Delaware corporation (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock (the “Common Stock”) had failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was initially provided 180 calendar days, or until June 30, 2026, to regain compliance.

On July 1, 2026, the Company received a notification letter from Nasdaq informing the Company that, while the Company has not yet regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until December 28, 2026 (the “Second Compliance Period”), to regain compliance.

If at any time during the Second Compliance Period, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide the Company with written confirmation of compliance. If compliance with the Minimum Bid Price Requirement cannot be demonstrated by December 28, 2026, Nasdaq will provide written notification that the Common Stock will be delisted from Nasdaq. At that time, the Company may appeal Nasdaq’s determination to a Hearings Panel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	RenovoRx, Inc.

Date: July 2, 2026	By:	/s/ Shaun R. Bagai
	Name:	Shaun R. Bagai
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents